截至6月30日，爱威科技股东户数4086.00，较上期增加13.34%；人均流通股16642股，较上期减少 11.77%。2025年1月-6月，爱威科技实现营业收入1.10亿元，同比增长12.70%；归母净利润1405.54万 元，同比增长21.16%。 10月9日，爱威科技跌1.51%，成交额3703.27万元。两融数据显示，当日爱威科技获融资买入额430.43 万元，融资偿还334.34万元，融资净买入96.09万元。截至10月9日，爱威科技融资融券余额合计4796.05 万元。 融资方面，爱威科技当日融资买入430.43万元。当前融资余额4796.05万元，占流通市值的2.76%，融资 余额超过近一年80%分位水平，处于高位。 融券方面，爱威科技10月9日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，爱威科技股份有限公司位于湖南省长沙市岳麓区学士街道茯苓路26号爱威医疗科技园，成立 日期2000年3月16日，上市日期2021年6月16日，公司主营业务涉及医疗临床检验分析仪器及配套体外 ...

资料显示，爱威科技股份有限公司位于湖南省长沙市岳麓区学士街道茯苓路26号爱威医疗科技园，成立 日期2000年3月16日，上市日期2021年6月16日，公司主营业务涉及医疗临床检验分析仪器及配套体外诊 断试剂、医用耗材的研发、生产、销售和服务。主营业务收入构成为：试剂45.63%，仪器34.53%，耗 材17.56%，其他(补充)2.28%。 从爱威科技十大流通股东角度 数据显示，诺安基金旗下1只基金位居爱威科技十大流通股东。诺安多策略混合A（320016）二季度新 进十大流通股东，持有股数47.74万股，占流通股的比例为0.7%。根据测算，今日浮亏损失约63.97万 元。连续3天下跌期间浮亏损失43.44万元。 诺安多策略混合A（320016）成立日期2011年8月9日，最新规模13.99亿。今年以来收益57.56%，同类 排名694/8172；近一年收益115.52%，同类排名360/7995；成立以来收益204.1%。 9月23日，爱威科技跌5.25%，截至发稿，报24.19元/股，成交1359.59万元，换手率0.81%，总市值16.45 亿元。爱威科技股价已经连续3天下跌，区间累计跌幅3.44%。 诺 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Aiwei Technology, which operates in the medical device industry [1][2] - As of July 4, Aiwei Technology's closing price was 21.42 yuan, with a PE ratio of 60.46, significantly higher than the industry average of 51.05 [1][2] - The company's total market capitalization is 1.457 billion yuan, ranking it 91st in the medical device industry based on PE ratio [1][2] Group 2 - For Q1 2025, Aiwei Technology reported a revenue of 53.2953 million yuan, representing a year-on-year increase of 13.85%, and a net profit of 6.321 million yuan, up 24.63% year-on-year [1] - The company's gross profit margin stands at 55.59%, indicating a strong profitability relative to its revenue [1] - Aiwei Technology holds a total of 259 authorized patents, including 97 domestic invention patents and 18 overseas patents, along with 30 software copyrights [1]

Core Viewpoint - Awei Technology has experienced a decline in profitability despite its growth in the in vitro diagnostic field since its listing on June 16, 2021, with a market value decrease from 26.04 billion yuan to 14.23 billion yuan over four years [1][3][5] Business Overview - Awei Technology's main business includes the research, production, sales, and service of medical clinical testing analysis instruments and supporting in vitro diagnostic reagents and medical consumables [3] - The core product revenue structure shows that reagents account for the highest proportion at 53.44%, followed by instruments at 25.17% [3] Financial Performance - In 2021, Awei Technology achieved a net profit attributable to shareholders of 0.31 billion yuan, which decreased to 0.23 billion yuan by the end of the latest complete fiscal year in 2024, reflecting a cumulative profit growth decline of 26.97% [3] - The company has not reported any annual losses in the past four years, with profit growth occurring in three out of four years, representing a 75.0% success rate [3] - Revenue remained relatively stable, with 2.11 billion yuan in 2021 and 2.03 billion yuan in 2024, indicating a lack of growth momentum [3] Market Capitalization - Awei Technology reached a market capitalization peak of 30.94 billion yuan and a stock price of 45.5 yuan on June 16, 2021, but as of June 13, the market cap has decreased to 14.23 billion yuan, resulting in a market value loss of 16.71 billion yuan, or 54.02% [5]

Core Viewpoint - The company is focused on expanding its AI image recognition technology applications in various medical testing fields, aiming to become a comprehensive service provider in medical laboratory equipment and related products [2][3]. Company Development and Technology - The company has diversified its product line in the medical testing instrument sector and is applying its core technology to blood, body fluid, pathology, and microbiological testing [2]. - The company has established a competitive advantage in the automation of clinical specimen microscopic examination, having entered this technology field early and developed a leading medical microscopic image database [4][5]. Industry Outlook - The high-end medical device industry is expected to have broad development prospects driven by national import substitution policies, technological innovation, and globalization strategies [3]. - The integration of artificial intelligence technology with modern diagnostic medicine is anticipated to accelerate the shift towards intelligent diagnostics in various fields [12]. Financial Performance - In 2024, the company achieved a net profit of 22.84 million yuan, a year-on-year increase of 6.07%, with a significant increase in net profit excluding non-recurring gains of 24.99% [10]. - For Q1 2025, the company reported a net profit of 6.32 million yuan, up 24.63% year-on-year, and a net profit of 5.01 million yuan after excluding non-recurring gains, reflecting a 48.77% increase [10][13]. Market Strategy - The company plans to maintain continuous R&D investment and product updates to sustain its competitive edge in the industry [8]. - Future growth drivers include expanding into new customer segments, particularly in grassroots and civilian markets, as well as international markets [8]. Product Applications - The company is leveraging machine vision and deep learning technologies to automate the analysis of microscopic components in clinical specimens, significantly improving accuracy and efficiency [5]. - The company is also exploring applications of its technology in non-medical fields such as aquatic biological detection and mineral testing [9].